Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) Treatment of COVID-19 in an Outpatient Setting

Next Previous
Trial Profile

A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) Treatment of COVID-19 in an Outpatient Setting

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Remdesivir (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms PINETREE
  • Sponsors Gilead Sciences

Most Recent Events

  • 19 Apr 2023 Results of subgroup analysis assessing heterogeneity of treatment effect (HTE) of early outpatient remdesivir, focusing on time from symptom onset and number of baseline risk factors published in the Infectious Diseases and Therapy
  • 22 Feb 2023 Results of analyzing Remdesivir Resistance in SARS-CoV-2 from the Phase 3 PINETREE ,presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023
  • 22 Feb 2023 Results assessing estimated dose exposure metrics of RDV and metabolites (GS-704277, GS-441524) in REDPINE (n=90) study compared to PINETREE (n=148) and REMDACTA(n=289) study participants presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top